



## Final program Thursday, Sep 20

8:15 - 8:30 am  
**Welcoming the participants:**  
*Alexander Eggermont*

**Introduction:**  
*Eric Deutsch*

### PRIMER ON CANCER IMMUNOLOGY AND IMMUNOTHERAPY



Society for Immunotherapy of Cancer

#### Session I: Immunology from the basics to the clinic

Moderators: A. Bobard-GRCC/E. Deutsch-GRCC

8:30 - 9:00 a.m.  
**Altered myelopoiesis in cancer**  
*Vincenzo Bronte, University of Verona*

9:00 - 9:30 a.m.  
**Adaptive T cell immunity**  
*Anna Mondino, San Raffaele University*

9:30 - 10:00 a.m.  
**State of the art clinical immunology:  
the melanoma revolution**  
*Alexander Eggermont, GRCC, Villejuif*

#### Session II: Immunotherapy from bench to bedside

Moderators: H. Fridman-CRC/E. Romano-Curie institute

10:30 - 11:15 am  
**Keynote IMMUNOLOGICAL CELL DEATH**  
**Immunogenic cell death in cancer therapy**  
*Guido Kroemer, CRC, Paris*

11:15 - 11:45 a.m.  
**Autophagy in cancer therapy – A quality-quantity  
conundrum**  
*Lorenzo Galluzzi, WCM, NY*

11:45 am - 12:15 noon  
**Immune contexture in the era of cancer immunotherapies**  
*Jérôme Galon, CRC, Paris*

12:15 am - 12:45 noon  
**Is there a role for radiation in the field of intratumoral  
immunotherapy?**  
*Aurélien Marabelle, GRCC, Villejuif*

### MAIN PROGRAM

#### Session I: From radiotherapy to immunotherapy and combinations

Moderators: S. Rivera-GRCC/P. Maingon-SFRO

2:00 - 2:30 pm  
**The basics of radiotherapy from Pierre Curie to  
carbon ions and radionuclides**  
*Cyrus Chargari, GRCC, Villejuif*

2:30 - 3:00 pm  
**Side effects of radiotherapy and immune treatment:  
How to mitigate them?**  
*Dirk de Ruyscher, MAASTRO clinic, Maastricht*

3:00 - 3:30 pm  
**What have we learned so far from phase 1 and 2  
immunoRad-trials?**  
*Piet Ost, UGhent*

3:30 - 4:15 pm  
**Keynote IMMUNOGENICITY**  
**The effects of radiotherapy on antigen processing  
and presentation**  
*William Mc Bride, UCLA*

#### Session II: Macrophages

Moderators: E. Solary-GRCC/M. Mondini-GRCC

4:45 - 5:15 pm  
**Macrophages reprogramming modulates the immune tumor  
microenvironment in mouse models of  
HPV-driven cervical cancer**  
*Enrico Giraudo, IRCC, Torino*

5:15 - 5:45 pm  
**What can we learn from the effects of irradiation of  
hematopoietic stem cells?**  
*Paul-Henri Roméo, CEA, Evry*

5:45 - 6:15 pm  
**Macrophage reprogramming, DNA damage response  
and radiation therapy**  
*Jean-Luc Perfettini, GRCC, Villejuif*

## COCKTAILS WITH POSTERS AND EXHIBITS

# Friday, Sep 21

### Session III: Innate sensors

Moderators: S. Postel-Vinay-GRCC/V. Soumelis-Curie institute

8:30 - 9:00 a.m.

#### **DNA damage sensing and innate immunity converge to regulate tumor-host interactions**

*Sandra Demaria, WCM, NY*

9:00 - 9:30 a.m.

#### **Pattern recognition receptor and interferon signaling in cancer and cancer immunotherapy**

*Andy Minn, UPenn, Philadelphia*

9:30 - 10:00 a.m.

#### **Pre-clinical and clinical data for combining immunotherapy plus radiation as systemic therapy**

*James Welsh, MDACC, Houston*

### Session IV: Tumor immune microenvironment

Moderators: C. Badoual-HEGP/S. Depil-Collectis

10:30 - 11:15 a.m. **Keynote T CELLS**

#### **Mechanisms regulating T-cell infiltration and activity in solid tumors**

*George Coukos, CHUV, Lausanne*

11:15 - 11:45 a.m.

#### **Altering the microenvironment for improving radio-immunotherapy**

*Tim Illidge, Manchester University*

11:45 - 12:15 a.m.

#### **Co-stimulation, co-inhibition and cross-priming at the crossroad of radio-immunotherapy**

*Ignacio Melero, CIMA, Pampelona*

12:15 am - 12:45 a.m. noon

#### **Clinical Translation of radio-immunotherapy combinations**

*Fernanda Herrera, CHUV, Lausanne*

2:00 - 2:45 pm

#### **Keynote OLIGOMETASTASIS**

#### **Oligometastasis and the immune contexture, how much do we have to treat?**

*Ralf Weichselbaum, Chicago University*

### Session V: Abscopal effect

Moderators: S. Demaria-WCM/S. Dovedi-Medimmune

2:45 - 3:15 pm

#### **Barriers to the abscopal effect of radiotherapy**

*Silvia Formenti, WCM, NY*

3:15 - 3:45 pm

#### **TCR clonal dynamics in mice and patients treated with radiotherapy and immune checkpoint blockade**

*Nils Rudqvist, WCM, NY*

3:45 - 4:15 pm

#### **Combining radiotherapy with checkpoint inhibitors and TGF $\beta$ inhibitors**

*David Raben, UColorado*

### Session VI: Viruses and microbes

Moderators: T. Naas-CHU Bicêtre/A. Bigorgne-GRCC

4:45 - 5:15 pm

#### **Modulating immune responses to radiation and viral therapies**

*Kevin Harrington, ICR, London*

5:15 - 5:45 pm

#### **Radiotherapy/Immunotherapy combinations the translational opportunities**

*Alan Melcher, ICR, London*

#### **5:45 - 6:30 pm Keynote MICROBIOME Microbiome and cancer**

*Laurence Zitvogel, GRCC, Villejuif*

### GALA DINNER

# Saturday, Sep 22

### Session VII: Radiomics

Moderators: N. Parajos-Centrale Supélec/C. Robert-GRCC

9:00-9:30

#### **Pseudo-progression: myth or reality?**

*Caroline Caramella, GRCC, Villejuif*

9:30-10:00

#### **Functional imaging to optimize the outcome of immunotherapy ?**

*Eric Deutsch, GRCC, Villejuif*

10:00-10:30 pm

#### **Radiomics and immunocytokines**

*Philippe Lambin, Maastricht University*

### Session VIII: Biomarkers

Moderators: JY Scoazec-GRCC/S. Michiels-GRCC

11:00-11:30 am

#### **Mathematical modeling of cancer immunotherapy and its synergy with radiotherapy**

*Dominique Barbolosi, Aix-Marseille University*

11:45-12:15 pm

#### **The histopathological effects of chemo(radio)therapy on regional lymph nodes in oesophageal cancer**

*Heike Grabsch, Maastricht University*

12:15-12:45 pm

#### **Germ-line microRNA biomarkers of radiation and immune toxicity**

*Johann B. Weidhaas, UCLA, USA*

12:45-1:00 pm

#### **Concluding remarks**

*Eric Deutsch*